MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 25, 2006; DOI: 10.1124/mol.106.025338


0026-895X/06/7003-947-959$20.00
Mol Pharmacol 70:947-959, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025338v1
70/3/947    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marks, M. J.
Right arrow Articles by Collins, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marks, M. J.
Right arrow Articles by Collins, A. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYTISINE

Deletion of the {alpha}7, beta2, or beta4 Nicotinic Receptor Subunit Genes Identifies Highly Expressed Subtypes with Relatively Low Affinity for [3H]Epibatidine

Michael J. Marks, Paul Whiteaker, and Allan C. Collins

Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado

Diversity of neuronal nicotinic acetylcholine receptor binding was measured using [3H]epibatidine after deletion of {alpha}7, beta2, or beta4 subunits. [3H]Epibatidine binding is distinctly biphasic. Densities of higher (Kd {approx} 0.02 nM) and lower (Kd {approx} 5 nM) affinity sites in whole brains of wild-type mice are very similar. Relative sensitivity to inhibition by cytisine or {alpha}-bungarotoxin was used to evaluate pharmacological subsets of the higher- and loweraffinity sites, respectively. Deletion of each subunit had distinct effects on the binding sites. Deletion of {alpha}7 did not affect higher-affinity sites but reduced the numbers of lower-affinity sites. This reduction was confined to the [3H]epibatidine binding sites sensitive to inhibition by {alpha}-bungarotoxin. Deletion of the beta2 subunit had the largest effect. Higher-affinity sites sensitive to inhibition by cytisine were eliminated, and cytisine-resistant sites were reduced. Deletion of the beta2 subunit also significantly reduced the number of lower-affinity sites insensitive to {alpha}-bungarotoxin. beta4 Gene deletion partially reduced cytisine-resistant and {alpha}-bungarotoxin-resistant sites with lower and higher affinity for [3H]epibatidine, respectively. Gene deletion in four brain regions (thalamus, hippocampus, superior colliculus, and inferior colliculus) elicited changes generally similar to whole brain. However, relative expression of the binding sites differed among the regions. [3H]Cytisine and 125I-{alpha}-bungarotoxin binding sites were eliminated by beta2 and {alpha}7 gene deletion, respectively. These studies establish that the lower-affinity sites represent a structurally diverse set of sites that require expression of either {alpha}7, beta2, or beta4 subunits and extend and confirm previous classifications of the higher-affinity [3H]epibatidine binding sites.


Received for publication April 6, 2006.

Accepted for publication May 23, 2006.

Address correspondence to: Dr. Michael J. Marks, Institute for Behavioral Genetics, 447 UCB, University of Colorado, Boulder, CO 80309. E-mail: marksm{at}colorado.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. Innocent, P. D. Livingstone, A. Hone, A. Kimura, T. Young, P. Whiteaker, J. M. McIntosh, and S. Wonnacott
{alpha}Conotoxin Arenatus IB[V11L,V16D] Is a Potent and Selective Antagonist at Rat and Human Native {alpha}7 Nicotinic Acetylcholine Receptors
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 529 - 537.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Gotti, M. Moretti, N. M. Meinerz, F. Clementi, A. Gaimarri, A. C. Collins, and M. J. Marks
Partial Deletion of the Nicotinic Cholinergic Receptor {alpha}4 or {beta}2 Subunit Genes Changes the Acetylcholine Sensitivity of Receptor-Mediated 86Rb+ Efflux in Cortex and Thalamus and Alters Relative Expression of {alpha}4 and {beta}2 Subunits
Mol. Pharmacol., June 1, 2008; 73(6): 1796 - 1807.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. C. Drisdel, D. Sharp, T. Henderson, T. G. Hales, and W. N. Green
High Affinity Binding of Epibatidine to Serotonin Type 3 Receptors
J. Biol. Chem., April 11, 2008; 283(15): 9659 - 9665.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Teper, D. Whyte, E. Cahir, H. A. Lester, S. R. Grady, M. J. Marks, B. N. Cohen, C. Fonck, T. McClure-Begley, J. M. McIntosh, et al.
Nicotine-Induced Dystonic Arousal Complex in a Mouse Line Harboring a Human Autosomal-Dominant Nocturnal Frontal Lobe Epilepsy Mutation
J. Neurosci., September 19, 2007; 27(38): 10128 - 10142.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. I. Damaj, C. Fonck, M. J. Marks, P. Deshpande, C. Labarca, H. A. Lester, A. C. Collins, and B. R. Martin
Genetic Approaches Identify Differential Roles for {alpha}4beta2* Nicotinic Receptors in Acute Models of Antinociception in Mice
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1161 - 1169.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics